Información del artículo
Resumen
En este artículo hacemos una completa revisión de la Historia de los corticoides desde Thomas Addison quien describió las características de la enfermedad que lleva su nombre, pasando por Edward Kendall quien fue el primero en sintetizar el compuesto E o cortisona, Philipe Hench y su grupo quienes hicieron la aplicación clínica de los glucorticoides en una paciente con artritis reumatoide, hasta llegar a Meyer Hermann con los conceptos actuales sobre ciclo circadioano. Es una historia fascinante que nos permite conocer en detalle todos los pasos que llevaron al descubrimiento de los corticoides y su aplicación clínica en diferentes enfermedades como la artritris reumatoide y el lupus eritematoso sistémico.
Palabras clave:
historia
glucocorticoides
mineralocorticoides
artritis reumatoide
lupus eritematoso sistémico
Summary
In this paper we do a complete review of the history of steroids from Thomas Addison, who described the characteristics of the disease that bears his name, through Edward Kendall who was the first to synthesize the compound E or cortisone, Philipe Hench and his group who made the clinical application of glucocorticoids in a patient with rheumatoid arthritis, up to Hermann Meyer with current concept on circadian rhytms. It is a fascinating story that lets us know in detail all the steps that led to the discovery of steroids and its clinical application in various diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Key words:
history
glucocorticoids
mineralocorticoids
rheumatoid arthritis
systemic lupus erythematosus
El Texto completo está disponible en PDF
Referencias
[1.]
L. Estralgo.
Historia de la medicina moderna y contemporánea.
Médico-científica, (1963), pp. 433-434
[2.]
G. Thorn.
Diagnosis end Treatment of Adrenal Insufficiency.
Thomas, (1951),
[3.]
W. Stoll.
Die Psychiatrie des Morbus Addison.
Thieme Verlag, (1953),
[4.]
Ingle D. Edward C. Kendall (1866-1972) Nat Acad of Sciences, Washington D.C. pp. 246-290.
[5.]
Iglesias Gamarra Antonio. Historia del Lupus. Panamericana. Formas e impresos Primera edición agosto 2003, pp. 503-513.
[6.]
P.S. Hench, E.C. Kendall, C.H. Slocumb, H.F. Polley.
Effect of a hormone of the adrenal cortex (17 Hydroxy – 11 Dehicrocosticosterone Compound E) and of pituitary adrenocorticotropic hormone on Rheumatoid Arthritis: Preliminary Report.
Proc Staff Meet Mayo Clinic, 24 (1949), pp. 181-197
[7.]
P.S. Hench, E.C. Kendall, C.H. Slocumb, H.F. Polley.
The Effect of Cortisone and of ACTH on rheumatoid arthritis and rheumatic fever.
Memorias del VII Congreso Internacional sobre Enfermedades Reumáticas, edición a cargo del Comité de Publicaciones, pp. 131-148
[8.]
P.S. Hench.
A Reminiscence of certain events before, during, and after the discovery of cortisone.
Minn Med, 36 (1953), pp. 705-710
[9.]
D.J. Ingle, B.L. Baker.
Physiological and therapeutic effects of corticotropin (ACTH) and cortisone.
Charles C. Thomas, (1953),
[10.]
P.S. Hench, E.C. Kendall, C.H. Slocumb, H.F. Polley.
Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions: A Study in Clinical Physiology.
Arch Inter Med, 85 (1950), pp. 545-666
[11.]
C.J. Smyth, R.H. Freyberg, C. McEwen.
History of rheumatology in the United States.
Arthritis Foundation, (1985),
[12.]
H.F. Polley.
Discovery of Anti-Inflammatory effects of cortisone and corticotrophin. Landamark advances in rheumatology.
American Association by Contact Associates International, Ltd, (1985), pp. 9-11
[13.]
P.S. Hench.
The Reversibility of Certain rheumatic and nonrheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone.
Ann Inter Med, 36 (1952), pp. 1-38
[14.]
P.S. Hench.
The Reversibility of certain rheumatic and non – rheumatic conditions by the use of cortisone or the pituitary adreno cortico tropic hormone: Nobel Lectures. Les Prix Nobel en 1950.
Nortedest Soner, (1951), pp. 195-223
[15.]
H.F. Polley, C.H. Slocumb.
Behind the scenes with cortisone and ACTH.
Mayo Clinic Proc, 51 (1976), pp. 471-477
[16.]
H.F. Polley.
Evolution of Ssteroids and their value in the control of rheumatic disease.
Mayo Clin Proc, 45 (1970), pp. 1-12
[18.]
J.L. Hollander, B.M. Brown, R.A. Jessar, C.V. Brown.
Hydrocortisone and cortisone iInjected into arthritic joints: Comparative Effects of and use of Hydrocortisone as Local Anti-Arthritic Agent.
JAMA, 147 (1951), pp. 1629-1633
[19.]
J.J. Bunim, M.M. Pecket, A.J. Bollet.
Studies on metacostandrolone and metacostandracin in rheumatoid arthritis.
JAMA, 157 (1955), pp. 311-316
[20.]
H.G. Kunkel, E.M. Tan.
Autoantiboides and disease.
AV Immunol, 4 (1964), pp. 351-395
[21.]
J.R. Elkinton, A.D. Hundt, L. Godfrey, W.W. McCrory, A.G. Rogerson, J. Stokes.
Effects of pituitary adrenocorticotropic hormone (ACTH) therapy.
JAMA, 141 (1949), pp. 1279
[22.]
A.W. Grace, F.C. Combes.
Remission of disseminated lupus erythematosus induced by adrenocorticotrophin.
Proc Soc Exp Biol Med, 72 (1949), pp. 563-565
[23.]
A.M. Harvey, J.E. Howard, W.L. Winkenwerder, J.E. Bordley, R.A. Carey, A. Kattus.
Observations on effect of adrenocorticotropic hormone (ACTH) on disseminated lupus erythematosus, drug hypersensitivy reactin; and chronic bronchial asthma.
Trans Amer Clin. Climat. Assn, 61 (1950), pp. 221-228
[24.]
G.W. Thorn, T.B. Boyles, B.F. Massell, P.H. Forsham, S.R. Hill, S. Smith, J.E. Warren.
Studies on the relation of pituitary – adrenal function to rheumatic disease.
New Eng J. Med, 241 (1949), pp. 529-537
[25.]
L.A. Brunsting, C.H. Slocumb, J.W. Didcoct.
Effects of cortisone on acute disseminated lupus erythematosus.
Proc Staff Meet Mayo Clin, 25 (1950), pp. 479-482
[26.]
L.J. Soffer, M.F. Levitt, G. Baehr.
Use of cortisone and adrenocorticotropin in disserminated lupus erythematosus.
Arch Int Med, 86 (1950), pp. 558-573
[27.]
L.J. Soffer, J.L. Gabrilove, H.P. Laquer, et al.
Effects of anterior pituitary adrenocorticotropic hormone (ACTH) in myastenia gravis with tumor of thymus.
J. Mt. Sinai Hosp, 15 (1948), pp. 73-82
[28.]
L.J. Soffer, R. Bader.
Corticotropin and cortisone in acute disseminated lupus erythematosus.
JAMA, 149 (1952), pp. 1002-1008
[29.]
G. Baehr, L.J. Soffer.
Treatment of disseminated lupus erythematosus with cortisone and adrenocorticotropin.
Bull New York Acad Med, 26 (1950), pp. 229-236
[30.]
G. Baehr, M.F. Levitt, L.J. Soffer.
The Influence of cortisone and adrenocorticotropin in disseminated lupus erythematosus.
Tr. A. Am Physicians, 63 (1950), pp. 89-94
[31.]
L.J. Soffer, G. Baehr, M.F. Levitt, R. Bader.
The Blakiston Co., (1951), pp. 680-690
[32.]
L.J. Soffer, S.K. Elster, D.J. Hamerman.
Treatment of acute disseminated lupus erythematosus with corticotropin and cortisone AMA.
Arch Int Med, 93 (1954), pp. 503-514
[33.]
L.J. Soffer, H.H. Ludeman, G. Brill.
The Effect of corticotropin and adrenal steroid on the management of acute disseminated lupus erythematosus.
Ann New York Acad Sci, 61 (1955), pp. 418-423
[34.]
R.C. Muehrcke, R.M. Kark, C.L. Pirani, V.E. Pollak.
Lupus Nephritis: A Clinical and pathologic study based on renal biopsies.
Medicine, 36 (1957), pp. 1-145
[35.]
J.W. Conn, L.H. Louis, C.E. Wheeler.
Production of temporary diabetes mellitus in man with pituitary aadrenocorticotrophic hormone: relation to uric acid metabolism.
J. Lab. Clin Med, 33 (1948), pp. 651-655
[36.]
R.A. Carey, A.M. Harvey, J.E. Howard.
Effect of adrenocorticotropin hormone (ACTH) and cortisone on course of disseminated lupus eryhematosus and periarteritis nodosa.
Bull Johns Hopkins Hosp, 87 (1950), pp. 425-460
[37.]
M. Reiner.
Effect of Cortisone and adrenacorticotropin therapy on serum proteins in disseminated lupus erythematosus.
Proc Soc Exp Biol Med, 74 (1950), pp. 529-531
[38.]
P.F.A. Hoefer, G.H. Glaser.
The Effects of pituirary adrenocorticotropin hormone (ACTH) Therapy: electroencephalographic and neuropsychiatric changes in fifteen patients.
JAMA, 143 (1950), pp. 620-624
[39.]
D.M. Woodbury, S. Cheng, G. Sayers, L.S. Goodman.
Antagonism of adrenocorticotropic hormone and adrenal cortical extract desoxycorticosterone: electrolytes and electroshock threshold.
Am J Physiol, 160 (1950), pp. 217-223
[40.]
D. Vaillancourt, A.W. Grokoest, C. Ragan.
Absence of analgesia during induced hyperadrenalism.
Proc Soc Exp Biol Med, 78 (1951), pp. 383-385
[41.]
W.D. Robinson, W.Q. Wolfson, I.F. Duff.
The Blakiston Co., (1951), pp. 49-556
[42.]
J.H. Vaughan, T.B. Boyles, C.B. Favour.
The Response of serum gamma globulin level and complement titer to adrenocorticotropin hormone (ACTH) therapy in lupus erythematosus disseminatus.
J Lab Clin Med, 37 (1951), pp. 698-702
[43.]
N.F. Boas, L.J. Soffer.
The Effect of ACTH and cortisone on the serum hexosamine in SLE.
J Clin Endocrinol, 11 (1951), pp. 39-45
[44.]
W. Ransohoff.
The Blakiston Co, (1951), pp. 160-176
[45.]
L.P. Eliel, O.H. Pearson, C.D. West.
Excesive losses of sodium, chloride and water after administration of cortisone or ACTH suggesting adrenoscortical insufficiency (Abst.).
J Clin Investigation, 30 (1951), pp. 637-643
[46.]
B.I. Heller, W.E. Jacobsen, J.F. Hammarsten.
Effect of cortisone in glomerulonephrits and the nephropathy of disseminated lupus erythematosus.
Am J Med, 10 (1951), pp. 520-525
[47.]
A. Dorfman, N.S. Apter, K. Smull, D.M. Bergenstal, R.B. Ritcher.
Status Epilepticus coincident with use of pituitary adrenocorticotropic hormone; Report of Three Cases.
JAMA, 146 (1951), pp. 25-27
[48.]
J.R. Haserick, A.C. Corcoran, H.P. Dustan.
ACTH and cortisone in acute crisis of systemic lupus erythematosus.
JAMA, 146 (1951), pp. 643-645
[49.]
E.L. Dubois, R.R. Commons, P. Starr, C.S. Stein, R. Morrison.
Corticotropin and cortisone treatment for systemic lupus erythematous.
JAMA, 149 (1952), pp. 995-1002
[50.]
R. Klemperer, A.D. Pollack, G. Baehr.
Pathology of disseminated lupus erythematous, and evaluation of Osler‘s contributions.
Bull Johns Hopkins Hosp, 85 (1949), pp. 47-79
[51.]
P.A. Tumulty, A.M. Harvey.
The clinical course of disseminated lupus erythematosus: An evaluation of Osler's contributions.
Bull Johns Hopkins Hosp, 85 (1949), pp. 47-73
[52.]
M.A. Shearn, B. Pirofsky.
Disseminated lupus erythematosus; analysis of 34 cases.
Arch Inter Med, 90 (1952), pp. 790-807
[53.]
A.M. Harvey, L.E. Shulman, A. Tumulty, C.L. Conley, E.H. Schoenrich.
Systemic lupus erythematosus: Review of the literature and clinical analysis of 138 Cases.
Medicine, 33 (1954), pp. 291-437
[54.]
E.M. Irons, J.P. Ayer, R.G. Brown, S.H. Armstromg.
ACTH and cortisone in diffuse collagen disease and chronic dermatosis Differential therapeutic effects.
JAMA, 145 (1952), pp. 861-869
[55.]
R. Armas-Cruz, Harnecker, Parrochia.
Cortisona en el lupus eritematoso generalizado.
Rev Med de Chile, 80 (1952), pp. 442-449
[56.]
V.E. Pollak, C.L. Pirani, R.M. Kark.
Effect of large doses of prednisone on the renal lesions and life Span of patients with lupus glomerulonephritis.
J. Lab Clin Med, 57 (1961), pp. 495-511
[57.]
G.L. Ackerman, C.M. Nolan.
Adrenocortical responsiveness after alternate – day corticosteriod therapy.
N. Engl J Med, 278 (1968), pp. 405-409
[58.]
J.P. Drinkard, T.M. Stanley, L. Dornfeld, R.C. Austin, E.V. Barnett, C.M. Person, R.L. Vernier, D.A. Adams, H. Latla, H.C. Gonick.
Azathiporine and predsisone in the treatment of adults with lupus nephritis Clinical histological and immuological change with therapy.
Medicine, 49 (1970), pp. 411-432
[59.]
J.S. Cameron, M. Boulton-Jones, R. Robinson, C. Ogg.
Treatment of lupus nephritis with ciclophosmamide.
Lancet, 2 (1970), pp. 846-849
[60.]
T. Hadidi.
Ciclophosphamide in systemic lupus erythematosus.
Ann Rheum Dis, 29 (1970), pp. 673-676
[61.]
W.D. Shelp, J.M.B. Bloodworth, R.E. Rieselbach.
Effect of azathioprine on renal histology and function in lupus nephritis.
Arch Intern Med, 128 (1971), pp. 566-573
[62.]
M. Sztejnbok, A. Stewart, H. Diamond, D. Kaplan.
Azathioprine in the treatment of systemic lupus, erythematosus: A controlled study.
Arthritis Rheum, 14 (1971), pp. 639-645
[63.]
A.D. Steinberg, B. Kaltrieder, P.J. Stapes, E.J. Goetzl, N. Talal, J.L. Decker.
Cyclophosphamide in lupus nephritis: A controlled trial.
Ann Inter Med, 75 (1971), pp. 165-171
[64.]
E.W. Boland.
Clinical comparison of the new-antiinflamatory corticosteroids.
Ann Rheum Dis, 21 (1962), pp. 176-187
[65.]
S. Lieberman, S. Teich.
Recent trend in the biochemistry of steriod hormones.
Pharm Rev, 2 (1953), pp. 285-380
[67.]
L. Steroid Axelrod.
Textbook of Rheumatology, pp. 822-840
[68.]
R.H. Freyberg.
Corticotropina, cortisona e hidrocortisona.
Artritis y estados afines,
[69.]
G.W. Thorn, P.H. Forshman, T.F. Frawley, S.R. Hill, M. Roche, D. Staehelin, D.L. Wilson.
Medical Progress. The Clnical Usefulness of ACTH and Cortisone.
New Engl J Med, 242 (1950), pp. 824-834
[70.]
M.W. Ropes.
Observations on the natural course of disseminated lupus erythematosus.
Medicine, 43 (1964), pp. 387-391
[71.]
W.G. Waugh.
Monoarticular Osteoarthritis of the hip. Treatment by Acid Injection.
Brit Med J, 1 (1945), pp. 873-874
[72.]
R. Mawson.
Treatment of osteoarthritis by lactic acid iInjection.
Brit Med J, 2 (1946), pp. 691-695
[73.]
J. Walton, B.S. Watson, R.L. Ney.
Alternate-day vs. shorter internal steroid administration.
Arch Inter Med, 126 (1970), pp. 601-607
[74.]
D.C. Dale, A.S. Fauci, S.M. Wolff.
Alternate-Day Prednisone: Leukocyte Kinetics and Susceptibility to Injection.
N Engl J Med, 291 (1974), pp. 1154-1158
[75.]
G.L. Ackerman, C.M. Nolan.
Adrenocortical responsiveness after Alternate-day corticosteroid therapy.
N Engl Med, 278 (1968), pp. 405-411
[76.]
E.S. Cathcart, M.A. Scheinberg, B.A. Idelson, W.G. Couser.
Beneficial effects of methylprednisolone ‘pulse’ therapy in diffuse proliferative lupus nephritis Lancet, 24 (1976), pp. 163-166
[77.]
H.D. Perez, R.P. Kimberley, H.B. Kaplan, H. Edelson, R.D. Inman, I.M. Goldstein.
Effect of high-dose methylprednisolone infusion on polymorphonuclear leukocyte function in patients with systemic lupus erythematosus.
Arthritis Rheum, 24 (1981), pp. 641-647
[78.]
S.H. Boghossian, D.A. Isemberg, G. Whright, M.L. Snaith, A.W. Segal.
Effect of high – dose methylprednisolone therapy of phagocyte function in systemic lupus erythematosus.
Ann Rheum Dis, 43 (1984), pp. 541-550
[79.]
E.C. Lin, W.E. Knox.
Adaption op the rat liver Tyrosine – a – ketoglutarate transaminase.
Biochen Biophys Acta, 26 (1957), pp. 85-89
[80.]
O. Greengard, G. Acs.
The effect of actinomycin on the substrate and hormonal induction of liver enzymes.
Biochen Biophs Acta, 61 (1962), pp. 652-657
[81.]
O. Greengard, G. Acs.
The effect of actinomycin on the substrate and hormonal induction of liver enzymes.
Biochemica et Biophysica Acta (BBA) - Specialized Section on Nucleic Acids and Related Subjects, 4 (1962), pp. 652-653
[82.]
H.C. Pitot, C. Peraino, P.A. Morse, V.R. Potter.
Hepatoma tissue culture compared with adapting liver in vivo.
Natl Cancer Inst Mongr, 13 (1964), pp. 229-235
[83.]
E.B. Thompson, G.M. Tomkins, J. Curran.
Induction of tyrosine – a – ketoglurate transaminase by steroid hormones in a newly established tissue culture cell line.
Proc Natl Acad Sci USA, 56 (1966), pp. 296-303
[84.]
B. Peterkofsky, G.M. Tomkins.
Effects of inhibitors of nucleic acid synthesis or steroid – mediated induction of Thyrosine Aminotransferase in Hepatoma Cell Cultures.
J. Mol. Biol, 30 (1967), pp. 49-57
[85.]
B. Peterkofsky, G.M. Tomkins.
Evidence for the steroid induced accumulation of tyrosine aminotranferense messenger RNA in the absence of protein Synthesis.
Proc Natl Acad Sci USA, 60 (1968), pp. 222-229
[86.]
A. Munck, T. Brinck-Johnsen.
Specific and nonspecific physiocochemical interactions of glucocorticoids and related steroid with rat thymus cells in vitro.
J. Biol Chem, 253 (1968), pp. 55-56
[87.]
B.P. Schaumburg, E. Bkojesen.
Specificity and thermodynamic properties of the corticosteroid binding to a receptor of rat thymocytes in vitro.
Bicohen Biophys Acta, 170 (1968), pp. 172-178
[88.]
L.K. Johnson, J.P. Longenecker, J.D. Baxter, M.F. Dallman, E.P. Widmaier, N.L. Eberhardt.
Glucosteroid hormone action: a mechanism involving nuclear and non – nuclear pathways.
Br J Dermatl, 107 (1982), pp. 6-15
[89.]
L.K. Johnson, N.C. Lan.
B axter JD. Stimulation and inhibition of cellular functions by glucocorticoids: correlations with rapid Influences on chromatin structures.
J Biol Chem, 524 (1979), pp. 77-85
[90.]
L.K. Johnson, J.D. Baxter.
Regulation of gene expression by glucocorticoids: early effects preserved in isolated chromatin.
J. Biol Chem, 253 (1978), pp. 1991-1996
[91.]
J.D. Baxter, G.M. Tomkins.
The relationship between glucocorticoid binding and tyrosine aminotransferense induction in hepatoma tissue culture cell.
Proc Natl Acad Sci USA, 65 (1970), pp. 709-807
[92.]
J.D. Baxter, G.M. Tomkins.
Specific cytoplasmic glucocorticoid hormone receptors in hepatoma tissue culture cells.
Proc Natl Acad Sci USA, 68 (1971), pp. 932-937
[93.]
E.V. Jensen, T. Suzuki, T. Kwashima, W.E. Stympf, P.W. Jungblut, E.R. Desombre.
The two-step mechanism for the interaction of estradiol with rat uterus.
Proc Natl Acad Sci USA, 59 (1968), pp. 632-639
[94.]
S. Fang, S. Liao, Androgenreceptors:.
Steroid and Tissue Specific Retention of a 17 β– Hydorxy – 5 α – Androstan – 3 – One Protein Complex by the Cell Nuclei of Ventral Prostate.
J. Biol Chem, 246 (1971), pp. 16-22
[95.]
B.W. O’Malley.
Mechanisms of action of steroid hormones.
N. Engl. J Med, 284 (1971), pp. 370-377
[96.]
P.L. Ballard, J.D. Baxter, G.G. Rousseau, S.J. Higgins, G.M. Tomkins.
Cytoplasmic receptors for glucocorticoids: general presence in responsive mammalian tissues.
Endocrinol, 94 (1974), pp. 998-1005
[97.]
J.D. Baxter, G.G. Rosseau, M.C. Benson, R.L. Garcea, J. Ito, G.M. Tomkins.
Role of DNA and specific cytoplasmic receptor in glucocorticoid action.
Proc Natl Acad Sci USA, 69 (1972), pp. 1982-1991
[98.]
F. Hirata, Y. Notsu, M. Iwata, L. Parente, M. Di Rosa, R.J. Flower.
Identification of several species of phospholipase inhibitory protein(S) by radioinmunoassay for lipomodullin.
Nature, 278 (1979), pp. 456-459
[99.]
F. Hirata, E. Schiffman, K. Venkata-Subramanian, D. Salomon, J.A. Axelrod.
Phrospholipase Ax inhibitory protein in rabbit neutrophile induced by glucocorticoids.
Proc Natl Acad Sci U.S.A, 77 (1980), pp. 2533-2541
[100.]
F. Hirata, R. del Carmine, C.A. Nelson, J. Axelrod, E. Schiffman, A. Warabi, A.L. De Bals, M. Nirenberg, V. Manganiello, M. Vaughan, S. Kumagai, I. Green, J.L. Decker, A.D. Steinberg.
Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases.
Proc Natl Acad Sci USA, 78 (1981), pp. 3190-3196
[101.]
F. Hirata.
The regulation of lipomodulin, a phospholipase inhibitory protein in rabbit neutrophil, by phosphorylatin.
J. Biol Chem, 256 (1981), pp. 7730-7737
[102.]
R.J. Flower, G.J. Blackwell.
Anti inflamatory steroides induce biosynthesis of a phospholipase A2 inhibitor which prevent protaglandin generation.
Nature, 278 (1979), pp. 456-459
[103.]
G.J. Blackwell, R. Carmiccio, M. Di Rosa, R.J. Flower, L. Parente, P. Persica.
Macrocortin: A Polypeptide causing the anti-phospholipase effed Of glucocorticoids.
Nature, 278 (1980),
[104.]
R.I. Scheinman, P.C. Cogswell, A.K. Lofquist, A.K. Lofquist, A.S. Baldwin Jr..
Role of transcriptional activation of IkBα bol in medication of immunosupression by glucocorticoids.
Science, 270 (1995), pp. 283-286
[105.]
M. Auphan, J.A. Di Donato, C. Rosette.
inmunosupression by glucocorticoids: inhibition of NF – KB activity through induction of IkBα synthesis.
Science, 270 (1995), pp. 286-290
[106.]
D.T. Boumpas, G.P. Chrosusos, R.I. Wilder, T.R. Cupps, J.E. Balow.
Glucocorticoid therapy for immune – mediated diseases: Basic and clinical correlates.
Ann Inter Med, 119 (1993), pp. 1198-2008
[107.]
P. Rutgeerts, R. Lofberg, H. Malchow, et al.
Deflazacort. an alternative to prednisolone?.
Drug ther Bull, 37 (1999), pp. 57-58
[108.]
Rutgeerts P, Lofberg R, Malchow H, et al. A comparision of budesonide with prednisolone for active Crohn's disease. N Eng J Med 331: 842-845.
[109.]
N.Z. Lu, J.A. Cidlowski.
The origin and functions at multiple human glucocorticoid receptor isoforms.
Ann NY Acad Sci, 1024 (2004), pp. 102-103
[110.]
T. Rhen, J.A. Cidlowski.
Antiinflammatory Action of Glucocorticoids New mechanisms for old Drugs.
N Engl J Med, 353 (2005), pp. 1711-1723
[111.]
R.H. Straub, M. Cutolo.
Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management.
Arthritis Rheum, 56 (2007), pp. 399-408
[112.]
E. Haus.
Chronobiology in the endocrine system.
Adv Drug Deliv Rev, 59 (2007), pp. 985-1014
[113.]
G.D. Tharp, G.E. Foek Jr..
Rhytmic changes in rare of the mammalian heart an heart cells during prolonged Isolation Comp.
Bioch Physiol, 14 (1965), pp. 255-273
[114.]
R.V. Andrew, G.E. Folk Jr..
Circadian Metabolic Patterns In Cultured Hamster Adrenal Glands.
Comp Biochem Physiol, 11 (1964), pp. 393-409
[115.]
R.V. Andrews.
Circadian rhythms in adrenal organ cultures.
Gegenbaurs Morphologisches Jahrbuch, 117 (1917), pp. 89-98
[116.]
D. Whitmore, N.S. Foulkes, U. Strahle, P. Sassone-Corsi.
Zebrafish Clock rhythmic expression reveals independent peripheral circadian oscillators.
Nature Neuroscience, 1 (1998), pp. 701-707
[117.]
W.C. Engeland, M.M. Arnhold.
Neural circuitry in the regulation of adrenal corticosterone rhythmicity.
Endocrine, 28 (2005), pp. 325-332
[118.]
A.V. Edwards, C.T. Jones.
The effect of splanchnic nerve section on the sensitivity of the adrenal cortex to adrenocorticotrophin in the calf.
J Physiol, 390 (1987), pp. 23-31
[119.]
C.D. Walker.
Chemical sympathectomy and maternal separation affect neonatal stress responses and adrenal sensitivity to ACTH.
Am. J Physiol l, 268 (1995), pp. R1281-1288
[120.]
W.C. Engeland, D.S. Gann.
Splanchnic nerve stimulation modulates steroid secretion in hypophysectomized dogs.
Neuroendocrinology, 50 (1989), pp. 124-131
[121.]
D.C. Klein, R.Y. Moore, S.M. Reppert.
Suprachiasmatic Nucleus. The minds clock.
Oxford University Press, (1991),
[122.]
D.M. Berson.
Phototransduction in ganglion-cell photoreceptors.
Pflu Gers Archiv, 454 (2007), pp. 849-855
[123.]
M.W. Hankins, S.N. Peirson, R.G. Foster.
Melanopsin: an exciting photopigment.
Trends in neurosciences, 31 (2008), pp. 27-36
[124.]
T. Roenneberg, R.G. Foster.
Twilight times: light and the circadian system Photochem.
Photobiol, 66 (1997), pp. 549-561
[125.]
I. Provencio, G. Jiang, W.J. De Grip, W.P. Hayes, M.D. Rollag.
Melanopsin: An opsin in melanophores, brain, and eye.
Proc Natl Acad Sci, 95 (1998), pp. 340-345
[126.]
R.M. Buijs, A. Kalsbeek, T.P. van der Woude, J.J. van Heerikhuize, S. Shinn.
Suprachiasmatic nucleus lesion increases corticosterone secretion.
American Journal of Physiology, 264 (1993), pp. 1186-1192
[127.]
A. Kalsbeek, R.M. Buijs, J.J. van Heerikhuize, M. Arts, T.P. van derWoude.
Vasopressin-containing neurons of the suprachiasmatic nuclei inhibit corticosterone release.
Brain Research, 580 (1992), pp. 62-67
[128.]
A. Balsalobre.
Clock genes in mammalian peripheral tissues.
Cell Tissue Res, 309 (2002), pp. 193-199
[129.]
R.J. Konopka, S. Benzer.
Clock mutants of Drosophila melanogaster.
Proc Natl Acad Sci U S A, 68 (1971), pp. 2112-2116
[130.]
J.F. Feldman, M.N. Hoyle.
Isolation of circadian clock mutants of Neurospora crassa.
Genetics, 75 (1973), pp. 605-613
[131.]
D.K. Welsh, D.E. Logothetis, M. Meister, S.M. Reppert.
Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms.
Neuron, 14 (1995), pp. 697-706
[132.]
T. Roenneberg, M. Merrow.
‘What watch?.such much!’ Complexity and evolution of circadian clocks.
Cell and Tissue Research, 309 (2002), pp. 3-9
[133.]
I.C. Kowanko, M.S. Knapp, R. Pownall, et al.
Domiciliary self measurement in the rheumatoid arthritis and the demonstration of circadian rhythmicity.
Ann Rheum Dis, 41 (1982), pp. 453-455
[134.]
M. Cutolo, G. Maestroni, O. Aakre, B. Villagio, S. Capellino, P. Montagna, L. Fazzuoli, T. Veldi, T. Peets, E. Hertens, A. Sulli.
Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison.
Ann Rheum Dis, 64 (2005), pp. 212-216
[135.]
N. Petrovsky, L. Harrison.
The chronobiology of human cytokine production.
Int Rev Immunol, 16 (1998), pp. 635-649
[136.]
C. Salvarani, F. Cantini, G. Hunder.
Polymyalgia rheumatica and giant-cell arteritis Seminar.
Lancet, 372 (2008), pp. 234-245
[137.]
M. Cutolo, G. Maestroni, O. Aakre, B. Villagio, S. Capellino, P. Montagna, L. Fazzuoli, T. Veldi, T. Peets, E. Hertens, A. Sulli.
Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison.
Ann Rheum Dis, 64 (2005), pp. 212-216
[138.]
M. Meyer-Hermann, M.T. Figge, R.H. Straub.
Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis: a systems biology approach.
Arthritis Rheum, 60 (2009), pp. 2585-2594
[139.]
J.N. Hoes, J.W.G. Jacobs, M. Boers, et al.
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
Ann Rheum Dis, 66 (2007), pp. 1560-1567
[140.]
F. Buttgereit, G. Doering, A. Schaeffer, S. Witte, S. Sierakowski, E. Gromnica-Ihle, et al.
Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomized controlled trial.
Lancet, 371 (2008), pp. 205-214
[141.]
F. Buttgereit, G.R. Burmester, B.J. Lipworth.
Optimised glucocorticoid therapy: the sharpening of an old spear.
Lancet, 375 (2005), pp. 801-803
[142.]
M. Cutolo, R.H. Stranb, F. Buttgereit.
Circadian rhytms of nocturnal hormones in rheumatoid arthritis: translation from bench to bed side.
Ann Rheum Dis, 67 (2008), pp. 905-908
[143.]
F. Buttgereit, H. Xhou, M.J. Seibel.
Arthritis and endogenous glucocorticoids: the emerging role of the 11β HSD enzymes.
Ann Rheum Dis, 67 (2008), pp. 1201-1210
Copyright © 2010. Asociación Colombiana de Reumatología
